Пути повышения эффективности цитостатиков у больных дессеминированными солидными новообразованиями
Диссертация
Определенный прогресс, в настоящее время, достигнут в' связи с разработкой моноклональных антител (бевацизумаб, цетуксимаб и трастузумаб), которые, в сочетании с химиотерапией, продлевают жизнь пациентов диссеминированным колоректальным раком до 24-х месяцев и увеличивают общую выживаемость больных метастатическим раком молочной железы (Нег2/пеи-положительный) с 20,3 до 25,1 месяцев (Гарин A. M… Читать ещё >
Список литературы
- Вершинина С.Ф., Стуков А. Н. Справочник по экспериментальной терапии опухолей. СПб, 2008. 36 с.
- Гарин A.M. Вклад лекарственной терапии в повышение общей выживаемости онкологических больных. Материалы IX Российского онкологического конгресса 22−24 ноября 2005 г.
- Жуков Н.В. Современное состояние антиангиогенной терапии. Целевая терапия без мишени? // Практическая онкология. Т. 8. № 3. С. 164−172.
- Злокачественные новообразования в России в 2002 году / Под ред. В. И. Чиссова, В. В. Старинского, Г. В. Петровой. М.: МНИОИ им. П. А. Герцена, 2004. 256 с.
- Инжеваткин Е.В. Практикум по экспериментальной онкологии на примере асцитной карциномы Эрлиха: Метод, разработка / Краснояр. гос. ун-т. Красноярск, 2004. 10 с.
- Мерабишвили В.М. Выживаемость онкологических больных. СПб.: ООО «Фирма КОСТА», 2006. 440 с.
- Моисеенко В.М. Почему не улучшаются показатели общей выживаемости больных с диссеминированными солидными опухолями? // Вопросы онкологии. 2004. Т. 50. № 2. С. 149−156.
- Моисеенко В.М., Тюляндин С. А., Семиглазов В. Ф. Современное лекарственное лечение местнораспространенного и метастатического рака молочной железы. СПб.: издательство «Грифон», 1997. 254 с.
- Ю.Стуков А. Н., Иванова М. А., Никитин А. К., Сорокин Г. М., Коньков С. А. Индекс роста опухоли как интегральный критерий эффективности противоопухолевой терапии в эксперименте // Вопросы онкологии. 2001. Т. 47. № 5. С. 616−618.
- И.Эмануэль Н. М. Кинетика экспериментальных опухолевых процессов / Институт химической физики Академии наук СССР. М.: Наука, 1977. 419 с.
- Ajani J.A. Evolving chemotherapy for advanced gastric cancer// Oncologist. 2005. V. 10. № 3. P. 49−58.
- Alderton G.K. Tumour supression: full on // Nat Rev Cancer. 2009. V. 9. № 9. P/612.
- Almong N., Ma J., Raychowdhury R., Schwager C., Erber R., Short S., Hlatky L., Vajkoczy P., Huber P.E., Folkman J., Abollahi A. Transcriptional switch of dormant tumors to fast-growing angiogenic phenotype // Cancer Res. 2009. V. 69. № 3. P. 836−844.
- Avraamides C.J., Garmy-Susini В., Varner J.A. Integrins in angiogenesis and lymphangiogenesis // Nat Rev Cancer. 2008. V. 8. № 8. P. 604−617.
- Baumann M., Krause M., Hill R. Exploring the role of cancer, stem cells in radioresistance //Nat Rev Cancer. 2008. V. 8. № 7. P. 545−554.
- Bernard M.P., Bancos S., Sime P.J., Phipps R.P. Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise // Curr Pharm Des. 2008. V. 14. № 21. P. 2051−60.
- Bernstein J.A., Schubbert Т., Kong K., Mehta R.S. Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: clinical response in patients with breast cancer // Proc Am Soc Clin Oncol. 2006. V. 24. P. 584s.
- Bissery M.C. Preclinical pharmacology of docetaxel // Eur J Cancer. 1995. V. 31 A. Suppl. 4. P. 1−6.
- Bloom H.J., Richardson W.W., Harries E.J. Natural history of untreated breast cancer (1805−1933). Comparison of untreated and treated’cases according to histological grade of>malignancy // Br Med J. 1962. V. 2. № 5299. P.'213−221.
- Bocci G., Nicolaou K. C, Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs // Cancer Res. 2002. V. 62. № 23. P. 6938−6943.
- Bocci G., Francia G., Man S., Lawler J., Kerbel R.S. Trombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy // Proc Natl Acad Sci USA. 2003. V. 100. № 22. P. -12 917−12 922.
- Borst P., Jonkers J., Rottenberg S. What makes tumors multidrug resistant? // Cell Cycle. 2007. V. 6. № 22. P. 234−237.
- Bourhis J., Wilson G., Wibault P., Janot F., Bosq J., Armand J.P., Luboinski В., Malaise E.P., Eschwege F. Rapid tumor cell proliferation after induction chemotherapy in oropharyngeal cancer // Laryngoscope. 1994. V. 104. № 4. P. 468−472.
- Browder Т., Butterfield C.E., Kraling B.M., Shi В., Marshall В., O’Reilly M.S., Folkman J. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer // Cancer Res. 2000. V. 60. № 7. P. 1878−1886.
- Journal of Clinical Oncology. 2005. ASCO Annual Meeting Proceedings. V. 23. № 16S. P. 695.
- Cadron I., Leunen K., Amant F., Van Gorp Т., Neven P., Vergotc I. The «Leuven» dose-dense paclitaxel/carboplatin regimen in patients with recurrent ovarian cancer // Gynecol Oncol. 2007. V. 106. № 2. P. 354−361.
- Cameron D.A., Stein S. Drug Insight: intracellular inhibitors of HER2--clinical development of lapatinib in breast cancer // Nat Clin Pract Oncol. 2008. V. 5. № 9. P. 512−520.
- Chau I., Cunningham D. Treatment in advanced colorecal cancer: what, when and how? // Br J Cancer. 2009. V. 100. № 11. P. 1704−1719.
- Cheong K.A., Chrystal K., Harper P.G. A single centre retrospective review of oral cyclophosphamide in hormone-refractory prostate cancer // Presented at the 2005 Prostate Cancer Symposium, American Society for Clinical Oncology. 2005. abstract 310.
- Clements M.K., Jones C.B., Cumming M. Antiangiogenic potential of camptothecin and topotecan // Cancer Chemother Pharmacol. 1999. V. 44. P. 411−416.
- Cunningham D., Humblet Y., Siena S. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer // N Engl J Med. 2004: V. 351. P. 337−345.
- D’Adamo D: Advances in the treatment of gastrointestinal stromal tumor // Adv. Ther. 2009. V. 26. № 9. P. 826−837.
- Davis A.J., Tannock J.F. Repopulation of tumour cells between cycles of chemotherapy: a neglected factor // Lancet Oncol. 2000. V. 1. P. 86−93.
- De Vita V.T., Lawrence T.S., Rosenberg S.A. DeVita, Hellman and Rosenberg’s cancer: principles and practice of oncology / edited by V.T. DeVita. 8th edition, 2008. 3035 p.
- Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis // J Clin Oncol. 2008. V. 26. № 17. P. 2839−2845.
- Fandrey J. Erythropoietin Receptors on Tumor Cells: What Do They Mean? // Oncologist. 2008. V. 13. Suppl. 3. P. 16−20.
- Fidler I.J., Ellis L.M. Chemotherapeutic drugs more really is not better // Nat Med. 2000. V. 6. P. 500−502.
- Folkman J. Anti-Angiogenesis: New Concept for Therapy of Solid Tumors // Ann Surg. 1972. V. 175. № 3. P. 409−416.
- Fontana A, Bocci G., D’Arcangelo M., Gali C., Bursi S., Landi L., Fioravanti A., Orlandi P., Battaglini P., Caponi S., Antonuzzo A., Derosa L., Miniti
- Fung A.S., Wu L., Tannock I.F. Concurrent and sequential administration of chemotherapy and the Mammalian target of rapamycin inhibitor temsirolimus in human cancer cells and xenografts // Clin Cancer Res. 2009. V. 15. № 17. P. 5389−5395.
- Furuya M., Yonemitsu Y., Aoki I. Angiogenesis: complexity of tumor vasculature and microenvironment // Curr Pharm Des. 2009. V. 15. № 16. P. 1854−1867.
- Garcia A.A., Hirte H., Fleming G., Yang D., Tsao-Wei D.D., Roman L., Groshen S., Swenson S., Markland F., Gandara D., Scudder S., Morgan R., Chen
- Gart J.J., Krewski D., Lee P.N., Tarone R.E., Wahrendorf J. Statistical methods in cancer research. Volume III. The design and analysis of long-term animal experiments // IARC Sci Publ. 1986. V. 79. P. 1−219.
- Gasparini G. Metronomic scheduling: the future of chemotherapy? // The Lancet Oncol. 2001. V. 2. № 12. P. 733−740.
- Germano S., O’Driscoll L. Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine // Curr Cancer Drug Targets. 2009. V. 9. № 3. P. 398−418.
- Grant D., Williams Т., Zahaczewsky M., Dicker A.P. Comparison of antiangiogenic activities using paclitaxel (Taxol) and docetaxele (Taxotere) // Int. J. Cancer. 2003. V. 104. P. 121−129.
- Greenlee R.T., Hill-Harmon M.B., Murray Т., Thun M. Cancer statistics, 2001 //CA Cancer .T Clin. 2001. V. 51. № 1. P. 15−36.
- Hahn G.M., Bagshaw M.A., Evans R.G., Gordon L.F. Repair of potentially lethal lesions in x-irradiated, density-inhibited Chinese hamster cells: metabolic effects and hypoxia // Radiat Res. 1973. V. 55. № 2. P. 280−290.
- Hirata S., Matsubara Т., Saura R., Tateishi H., Hirohata K. Inhibition of in vitro vascular endothelial cell proliferation and in vivo neovascularisation by low-dose methotrexate //Arthritis Rheum. 1989. V. 32. № 9. P. 1065−1073.
- Hirsch F.R. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC // Oncogene. 2009. V. 28. Suppl. 1. P. 1−3.
- Hudis C. Testing chemotherapy for breast cancer: timing is everything // J Clin Oncol. 2005. V. 23. № 24. P. 5434−5436.
- Husain A., Aptaker L., Spriggs D.R., Barakat R.R. Gastrointestinal Toxicity and Clostridium Difficile Diarrhea in Patients Treated with Paclitaxel-Containing Chemotherapy Regimens // Gynecol Oncol. 1998. V. 71. № 1. P. 104−107.
- Jones C.B., Clements M.K., Wasi S., Daoud S.S. Sensitivity to camptothecin of human breast carcinoma and normal endothelial cells // Cancer Chemother Pharmacol. 1997. V. 40/№ 3. P. 475−483.
- Keime-Guibert F., Napolitano M., Delattre J.Y. Neurological complications of radiotherapy and chemotherapy // J Neurol. 1998. V. 245. № 11. P. 695−708.
- Kerbel R.S., Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy // Nat Rev Cancer. 2004. V. 4. № 6. P. 423−436.
- Kerbel R.S. Antiangiogenic therapy: a universal chemosensitization strategy for cancer? // Science. 2006. V. 312. № 5777. P. 1171−1175.
- Kerbel R.S. Tumor angiogenesis // N Engl J Med. 2008. V. 358. № 19. P. 2039−2049.
- Komarova N.L., Zou X., Nie Q., Bardwell L. A theoretical framework for specificity in cell signaling // Mol Syst Biol. 2005. V. 1. P. 1−5.
- Kurzen H., Schmitt S., Naher H., Mohler T. Inhibition of angiogenesis by non-toxic doses of temozolomide // Anticancer Drugs. 2003. V. 14. № 7. P. 515— 522.
- Le Tourneau C., Faivre S., Raymond E. New developments in multitargeted therapy for patients with solid tumours // Cancer Treat Rev. V. 34. № 1. P. 37−48.
- Longhi A., Ferrari S. Baeei G., Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma // Anticancer Drugs. 2007. V. 18. № 6. P. 737−744.
- Lord R, Nair S, Schache A, Spicer J, Somaihah N, Khoo V, Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study// J Urol. 2007. V. 177. № 6. P. 2136−40. Discussion 2140.
- Los M., Roodhart J.M., Voest E.E. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer // Oncologist. 2007. V. 12. № 4. P. 443−450.
- Lyman G.H. Impact of chemotherapy dose intensity on cancer patient outcomes // J Natl Compr Cane Netw. 2009. V. 7. № 1. P. 99−108.
- Maciejewski В., Withers H.R., Taylor J.M., Hliniak A. Dose fractionation and regeneration in radiotherapy for cancer of the oral cavity and oropharynx: tumor dose-response and repopulation // Int J Radiat Oncol Biol Phys. 1989. V. 16. № 3. P. 831−843.
- Marino P., Pampallona S., Preatoni A., Cantoni A., Invernizzi F. Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature // Chest. 1994. V. 106. № 3. P. 861−865.
- Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease // Nat Rev Cancer. V. 9. № 9. P. 665−674.
- Mendoza L. Targeted therapies in the treatment of advanced non-small-cell lung cancer: update // Klin Onkol. 2009. V. 22. № 4. P. 131−138.
- Miller K. D, Sweeney C.J., Sledge' G.W. Redefining the target: chemotherapeutics as antiangiogenics // J Clin Oncol. 2001. V. 19. № 4. P. 1195−1206.
- Minchinton A.I., Tannock I.F. Drug penetration in solid tumours // Nat Rev Cancer. 2006. V. 6. № 8. P. 583−592.
- Mizobe Т., Ogata Y., Murakami H., Akagi Y., Ishibashi N., Mori S., Sasatomi Т., Shirouzu K. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma // Oncol Rep. 2008. V. 20. P. 517−523.
- Munoz R., Shaked Y., Bertolini F., Emmenegger U., Man S., Kerbel R.S. Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy // Breast. 2005. V. 14. P. 466−479.
- Munstedt K., Manthey N., S. Sachsse S., Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy // Support Care Cancer. 1997. V. 5. № 2. P. 139−143.
- Mutsaers A.J. Metronomic chemotherapy // Top Companion Anim Med. 2009. V. 24. № 3. P. 137−143.
- Nicolini A., Mancini P.A., Ferrari P., Anselmi L., Tartarelli G., Bonazzi V., Carpi A., Giardino R. Oral low-dose cyclophosphamide in Metastatic Hormone Refractory Prostate Cancer (MHRPC) // Biomedicine & Pharmacotherapy. 2004. V. 58. № 8. P. 447−450.
- Norton L. Conceptual and Practical Implications of Breast Tissue Geometry: Toward a More Effective, Less Toxic Therapy // Oncologist. 2005. V. 10. № 6. P. 370−381.
- Parkin D.M., Wabinga H., Nambooze S., Wabwire-Mangen F. AIDS-related cancers in Africa: maturation of the epidemic in Uganda // AIDS. 1999. V. 13. № 18. P. 2563−2570.
- Parkin D.M., Bray F., Ferlay J., Pisani P. Estimating the world cancer burden: Globocan 2000 // Int J Cancer. 2001. V. 94. № 2. P. 153−156.
- Perez-Soler R. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice // Oncogene. 2009. V. 28. Suppl. 1. P. 38−45.
- Pietras K., Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose «chemo-switch» regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer // J Clin Oncol. 2005. V. 23. № 5. P. 939−952.
- Rafii S., Lyden D., Benezra R., Hattori K., Heissig B. Vascular and haematopoetic stem cells: novel targets for antiangiogenesis therapy? // Nat Rev Cancer. 2002. V. 2. № 11. p. 826−835.
- Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma // Lancet Oncol. 2009. V. 10. № 10. P. 992−1000.
- Rosen L.S. VEGF-targeted therapy: therapeutic potential and recent advances // Oncologist. 2005. V. 10. № 6 P. 382−391.
- Schabel F.M. The use of tumor growth kinetics in planning «curative» chemotherapy of advanced solid tumors // Cancer Res. 1969. V. 29. № 12. P. 2384−2389.
- Schatton Т., Frank M.H. Antitumor immunity and cancer stem cells // Ann N Y Acad Sci. 2009. V. 1176. P. 154−169.
- Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., Zhu J., Johnson D.H. Comprassion of four chemotherapy regimens for advanced non-small-cell lung cancer // N Engl J Med. 2002. V. 346. № 2. P. 92−98.
- Schmidt C. Resistance revisited: looking back at 10 years of multidrug resistance research // J Natl Cancer Inst. 2008. V. 100. № 20. P. 1428−1429.
- Semenza GL. HIF-1 Inhibitors for Cancer Therapy: From Gene Expression to Drug Discovery // Curr Pharm Des. 2009. V. 15. № 33. P. 3839−3843.
- Sequist L.V., Bell D.W., Lynch T.J., Haber D.A. Molccular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer // J Clin Oncol. 2007. V. 25. № 5. P. 587−595.
- Shaked Y., Emmenegger U, Man S., Cervi D., Bertolini F., Ben-David Y., Kerbel R.S. The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity // Blood. 2005. V. 106. № 9. P. 3058−3061.
- Shibuya M. Brain angiogenesis in developmental and pathological processes: therapeutic aspects of vascular endothelial growth factor // FEBS J. 2009. V. 276. № 17. P. 4636−4643.
- Simon R., Norton L. The Norton-Simon hypothesis: designing more effective and less toxic chemotherapeutic regimens // Nat Clin Pract Oncol. 2006. V. 3. № 8. P. 406−407.
- Sobrero M.F., Maurel J., Fehrenbacher L. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropirymidine and oxalipltin failure in patients with metastatic colorectal cancer // Journal of clinical oncology. 2008. V. 26. P. 2311−2319.
- Soria J.C., Fayette J., Armand J.P. Molecular targeting: targeting angiogenesis in solid tumours //Ann Oncol. 2004. V. 15. Suppl. 4. P. 223−227.
- Speer J.F., Petrovsky V.E., Retsky M.W., Wardwell R.H. A stochastic numerical model of breast cancer growth that stimulates clinical data // Cancer Res. 1984. V. 44. № 9. p. 4124−4130.
- Spieth К, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study // Cancer Chemother Pharmacol. 2003. V. 52. № 5. P. 377 ±382.
- Stephens T.C., Peacock J.H. Tumour volume response, initial ccll kill and cellular repopulation in В16 melanoma treated with cyclophosphamide and l-(2-chloroethyl)-3-cyclohexyl-l-nitrosourea // Br J Cancer 1977. V. 36. № 3. P. 313−321.
- Stephens T.C., Peacock J.H. Comparison of growth delay and cell survival as end-points of tumour response following treatment with combinations of cytotoxic agents // Br J Cancer. 1980. V. 4. P. 288−293.
- Strijbos M.H., Verhoef C., Gratama J.W., Sleijfer S. On the origin of (CD105+) circulating endothelial cells // Thromb Haemost. 2009. V. 102. № 2. P. 347−351.
- Tanigawa N., Amaya H., Matsumura M., Shimomatsuya T. Correlation Between Expression of Vascular Endothelial Growth Factor and Tumor Vascularity, and Patient Outcome in Human Gastric Carcinoma // J Clin Oncol. 1997. V. 15. № 2. P. 826−832.
- Tappenden P, Jones R., Paisley S., Carroll C. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales // Eur J Cancer. 2007. V. 43. № 17. P. 2487−2494.
- Tjan-Heijnen V.C., Wagener D.J., Postmus P.E. An analysis of chemotherapy dose and dose-intensity in small-cell lung cancer: lessons to be drawn//Ann Oncol. 2002. V. 13. № 10. P. 1519−1530.
- Toomey D.P., Murphy J.F., Conlon K.C. COX-2, VEGF and tumour angiogenesis // Surgeon. 2009. V. 7. № 3. P. 174−80.
- Tyagi P. Vatalanib (PTK787/ZK 222 584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial // Clin Colorectal Cancer. 2005. V. 5. № 1. p. 24−26.
- Vacca A., Iurlaro M., Ribatti D., Minischetti M., Nico В., Ria R., Pellegrino A., Dammacco F. Antiangiogenesis is produced by nontoxic doses of vinblastine // Blood. 1999. V. 94. № 12. P. 4143−4155.
- Vitello S., Maiorana O.D., Giarratano G., Triglia E., Mangione M., Di Cristina L. A metronomic treatment with oral chemotherapy in patients elderly with metastatic breast cancer // European Journal of Cancer Supplements. 2008. V. 6. № 14. P. 116−117.
- Watanabe Y., Nakai H., Ueda H., Hoshiai H. Evaluation of weekly low-dose paclitaxel and carboplatin treatment for patients with platinum-sensitive relapsed ovarian cancer // Gynecologic Oncology 2005. V. 96. № 2. P. 323−329.
- Wijffels K.I., Marres H.A., Peters J.P., Rijken P.F., van der Kogel A.J., Kaanders J.H. Tumour cell proliferation under hypoxic conditions in human head and neck squamous cell carcinomas // Oral Oncol. 2008. V. 44. № 4. P. 335−344.
- Wiley J.S., Firkin F.C. Reduction of pulmonary toxicity by prednisolone prophylaxis during all-trans retinoic acid treatment of acute promyelocytic leukemia// Leukemia. 1995. V. 9. № 5. p. 774−778.
- Wils J. The treatment of advanced gastric cancer // Semin Oncol. V. 23. № 3. P. 397−406.161 .Wilson G.D. Cell kinetics // Clin Oncol. 2007. V. 19. № 6. P. 370−384.
- Wu L., Tannock I.F. Repopulation in murine breast tumors during and after sequential treatments with cyclophosphamide and 5-fluorouracil // Cancer Res. 2003. V. 63. № 9. P. 2134−2138.
- Zeng L., Yan Z., Ding S., Xu K., Wang L. Endothelial Injury, an Intriguing Effect of Methotrexate and Cyclophosphamide During Hematopoietic Stem Cell Transplantation in Mice // Transplantation Proceedings. 2008. V. 40. № 8. P. 2670−2673.